GleamWall
中文EN

GRI GRI Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1824293 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY30.6%
TTM EPS YoY101.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-144.6%
ROA-107.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets9.8%
Debt / equity0.00x
Current ratio10.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.23x
Accruals ratio24.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$212,000$407,000$361,000$1.63M$1.77M$1.88M$1.64M$829,000
SG&A expense$1.30M$1.24M$1.64M$1.03M$1.60M$1.02M$1.41M$1.12M
Operating income-$1.51M-$1.65M-$2.00M-$2.66M-$3.37M-$2.90M-$3.05M-$1.95M
Net income-$1.51M-$1.64M-$2.00M-$2.66M-$3.36M-$2.89M-$3.05M-$1.95M
EBITDA-$1.51M-$1.65M-$2.00M-$2.66M-$3.36M-$2.90M-$3.05M-$1.95M
EPS (basic)-0.69-0.91-1.61—-35.88-36.72-162.30—
EPS (diluted)-0.69-0.91-1.61—-35.88-36.72-162.30—
Weighted avg. shares (diluted)2.19M1.80M1.24M—93,62778,75718,768—
Balance sheet
Cash & equivalents$9.47M$10.95M$11.05M$8.23M$4.05M$5.12M$3.28M$5.03M
Current assets$9.73M$11.33M$11.28M$8.59M$4.70M$5.58M$3.93M$5.62M
PP&E, net$2,000$2,000$2,000$3,000$1,000$2,000$3,000$4,000
Total assets$9.76M$11.38M$11.34M$8.67M$4.78M$5.67M$4.04M$5.74M
Current liabilities$953,000$1.10M$794,000$2.64M$2.76M$2.31M$2.78M$1.64M
Total liabilities$953,000$1.10M$794,000$2.66M$2.79M$2.35M$2.84M$1.71M
Shareholders' equity$8.81M$10.28M$10.54M$6.01M$1.99M$3.32M$1.21M$4.03M
Shares outstanding2.19M2.19M1.58M497,6933.27M2.50M525,35818,768
Cash flow statement
Operating cash flow-$1.48M-$1.45M-$3.69M-$2.97M-$2.31M-$3.17M-$1.74M-$2.00M
Capital expenditure———————$0
Free cash flow———————-$2.00M
Investing cash flow———————$0
Financing cash flow$0$1.34M$6.50M$7.15M$1.25M$5.01M-$11,000$2.28M
Depreciation & amortization$0$0$1,000$1,000$1,000$1,000$1,000$1,000
Stock-based compensation$33,000$34,000$31,000$67,000$465,000$41,000$220,000$37,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.